IL1B and Alzheimer disease: We therefore stratified the AD patient samples by MMSE score into three equal-sized subgroups reflecting very mild, mild and moderate clinical AD stages and found that in the MMSE (11–18) group (moderate AD) IL-1β was significantly increased compared to age-matched controls (p < 0.05) (Fig. 3), while the mild MMSE (≥24) and the mild to moderate MMSE (18–23) showed no statistically significant difference.